Rebamipide during chronic gastritis: H. pylori eradication therapy and restoration of gastric mucosa barrier function
https://doi.org/10.22416/1382-4376-2023-33-6-81-87
Abstract
Аim: to present evidence justifying prescription of rebamipide during chronic gastritis.
Key points. Experimental and clinical studies have demonstrated that rebamipide increases concentration of prostaglandins (prostaglandin E2 and prostacyclin) and production of mucin, manages inflammation and oxidative stress, controls apoptosis and autophagy. Pleiotropic effects of rebamipide are aimed at restoration of epithelium barrier function and can be implemented during chronic gastritis for various indications. When added to the H. pylori eradication therapy, rebamipide increases its effectiveness and tolerability. During atrophic gastritis, long-term treatment with rebamipide has resulted in reduction of degree of atrophy and intestinal metaplasia. Effectiveness of rebamipide during erosive gastritis, for treatment and prevention of stomach and duodenum disorders associated with nonste- roidal anti-inflammatory drugs is proven. Rebamipide manages symptoms of dyspepsia during chronic gastritis and during functional dyspepsia.
Conclusion. Prescription of rebamipide during chronic gastritis for various indications is proved from the perspective of evidence-based medicine during H. pylori eradication therapy and for restoration of mucosa barrier function.
About the Authors
Т. L. Lapina
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Russian Federation
Tatiana L. Lapina — Cand. Sci. (Med.), Assoc. Prof., Chair of Internal Disease Propaedeutics, Gastroenterology and Hepatology
119435, Moscow, Pogodinskaya str., 1, bld. 1
V. T. Ivashkin
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Russian Federation
Vladimir T. Ivashkin — Dr. Sci. (Med.), RAS Academician, Prof., Departmental Head, Department of Propaedeutics of Internal Diseases, N.V. Chief of Vasilenko Clinic of Internal Disease Propaedeutics, Gastroenterology and Hepatology
119435, Moscow, Pogodinskaya str., 1 bld. 1
References
1. Aksenova E.A., Podchernina A.M. (ed.). Morbidity indicators for the population of the city of Moscow for 2018–2022. M.: State Budgetary Institution "NIIOZMM DZM", 2023.
2. Bordin D., Morozov S., Plavnik R., Bakulina N., Voynovan I., Skibo I. et al. Helicobacter pylori infection prevalence in ambulatory settings in 2017–2019 in Russia: The data of real-world national multicenter trial. Helicobacter. 2022;27(5):e12924. DOI: 10.1111/hel.12924
3. Ivashkin V.T., Maev I.V., Lapina T.L., Fedorov E.D., Sheptulin A.A., Trukhmanov A.S., et al. Clinical Recommendations of Russian Gastroenterological Association and RENDO Endoscopic Society on Diagnosis and Treatment of Gastritis and Duodenitis. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2021;31(4):70–99. (In Russ.). DOI: 10.22416/1382-4376-2021-31-4-70-99
4. Chiang T.H., Maeda M., Yamada H., Chan C.C., Chen S.L., Chiu S.Y., et al. Risk stratification for gastric cancer after Helicobacter pylori eradication: A population-based study on Matsu Islands. J Gastroenterol Hepatol. 2021;36(3):671–9. DOI: 10.1111/jgh.15187
5. Nishikawa Y., Ikeda Y., Murakami H., Hori S.I., Yoshimatsu M., Nishikawa N. Mucosal patterns change after Helicobacter pylori eradication: Evaluation using blue laser imaging in patients with atrophic gastritis. World J Gastroenterol. 2023;29(17):2657–65. DOI: 10.3748/wjg.v29.i17.2657
6. Arakawa T., Higuchi K., Fujiwara Y., Watanabe T., Tominaga K., Sasaki E., et al. 15th anniversary of rebamipide: looking ahead to the new mechanisms and new applications. Dig Dis Sci. 2005;50(Suppl 1):S3–11. DOI: 10.1007/s10620-005-2800-9
7. Genta R.M. Review article: The role of rebamipide in the management of inflammatory disease of the gastrointestinal tract. Aliment Pharmacol Ther. 2003;18(Suppl 1):8– 13. DOI: 10.1046/j.1365-2036.18.s1.5.x
8. Haruma K., Ito M. Review article: clinical significance of mucosal-protective agents: Acid, inflammation, carcinogenesis and rebamipide. Aliment Pharmacol Ther. 2003;18(Suppl 1):153–9. DOI: 10.1046/j.1365-2036.18.s1.17.x
9. Choi K.W., Lee Y.C., Chung I.S., Lee J.J., Chung M.H., Kim N.Y., et al. Effect of rebamipide in treatment of Helicobacter pylori-associated duodenal ulcer: attenuation of chemokine expression and nitrosative damage. Dig Dis Sci. 2002;47(2):283–91. DOI: 10.1023/a:1013753602149
10. Hahm K.B., Lee K.J., Kim Y.S., Kim J.H., Cho S.W., Yim H., Joo H.J. Quantitative and qualitative usefulness of rebamipide in eradication regimen of Helicobacter pylori. Dig Dis Sci. 1998;43(9 Suppl):192S–7S.
11. Naito Y., Kuroda M., Mizushima K., Takagi T., Handa O., Kokura S., et al. Transcriptome analysis for cytoprotective actions of rebamipide against indomethacin-induced gastric mucosal injury in rats. J Clin Biochem Nutr. 2007;41(3):202–10. DOI: 10.3164/jcbn.2007029
12. He Q., Liu M., Rong Z., Liang H., Xu X., Sun S., et al. Rebamipide attenuates alcohol-induced gastric epithelial cell injury by inhibiting endoplasmic reticulum stress and activating autophagy-related proteins. Eur J Pharmacol. 2022;922:174891. DOI: 10.1016/j.ejphar.2022.174891
13. Kong Y.J., Yi H.G., Dai J.C., Wei M.X. Histological changes of gastric mucosa after Helicobacter pylori eradication: A systematic review and meta-analysis. World J Gastroenterol. 2014;20(19):5903–11. DOI: 10.3748/wjg.v20.i19.5903
14. Nishizawa T., Nishizawa Y., Yahagi N., Kanai T., Takahashi M., Suzuki H. Effect of supplementation with rebamipide for Helicobacter pylori eradication therapy: A systematic review and meta-analysis. J Gastroenterol Hepatol. 2014;29(4):20–4. DOI: 10.1111/jgh.12769
15. Andreev D.N., Maev I.V., Dicheva D.T. Efficiency of the inclusion of rebamipide in the eradication therapy for Helicobacter pylori infection: Meta-analysis of randomized controlled studies. J Clin Med. 2019;8(9):1498. DOI: 10.3390/jcm8091498.
16. Andreev D.N., Maev I.V., Bordin D.S., Lyamina S.V., Dicheva D.T., Fomenko A.K., Bagdasarian A.S. Effectiveness of Rebamipide as a part of the Helicobacter pylori eradication therapy in Russia: A meta-analysis of controlled trials. Consilium Medicum. 2022;24(5):333–8. (In Russ.). DOI: 10.26442/20751753.2022.5.201863
17. Hayashi S., Sugiyama T., Amano K., Isogai H., Isogai E., Aihara M., et al. Effect of rebamipide, a novel antiulcer agent, on Helicobacter pylori adhesion to gastric epithelial cells. Antimicrob Agents Chemother. 1998;42(8):1895–9. DOI: 10.1128/AAC.42.8.1895
18. Wang H., Zhao M., Shi F., Zheng S., Xiong L., Zheng L. A review of signal pathway induced by virulent protein CagA of Helicobacter pylori. Front Cell Infect Microbiol. 2023;13:1062803. DOI: 10.3389/fcimb.2023.1062803
19. Kang D.W., Hwang W.C., Park M.H., Ko G.H., Ha W.S., Kim K.S., et al. Rebamipide abolishes Helicobacter pylori CagA-induced phospholipase D1 expression via inhibition of NFκB and suppresses invasion of gastric cancer cells. Oncogene. 2013;32(30):3531–42. DOI: 10.1038/onc.2012.358
20. Lee K.H., Kim J.Y., Kim W.K., Shin D.H., Choi K.U., Kim D.W., et al. Protective effect of rebamipide against Helicobacter pylori-CagA-induced effects on gastric epithelial cells. Dig Dis Sci. 2011;56(2):441–8. DOI: 10.1007/s10620-010-1299-x
21. Kang D.W., Noh Y.N., Hwang W.C., Choi KY., Min do S. Rebamipide attenuates Helicobacter pylori CagA-induced self-renewal capacity via modulation of β-catenin signaling axis in gastric cancer-initiating cells. Biochem Pharmacol. 2016;113:36–44. DOI: 10.1016/j.bcp.2016.06.003
22. Matysiak-Budnik T., Heyman M., Mégraud F. Review article: Rebamipide and the digestive epithelial barrier. Aliment Pharmacol Ther. 2003;18(Suppl 1):55–62. DOI: 10.1046/j.1365-2036.18.s1.6.x
23. Simanenkov V.I., Maev I.V., Tkacheva O.N., Alekseenko S.A., Andreev D.N., Bordin D.S., et al. Syndrome of increased epithelial permeability in clinical practice. Multidisciplinary national Consensus. Cardiovascular Therapy and Prevention. 2021;20(1):2758. (In Russ.). DOI: 10.15829/1728-8800-2021-2758
24. Haruma K., Ito M., Kido S., Manabe N., Kitadai Y., Sumii M., et al. Long-term rebamipide therapy improves Helicobacter pylori-associated chronic gastritis. Dig Dis Sci. 2002;47(4):862–7. DOI: 10.1023/a:1014716822702
25. Kamada T., Sato M., Tokutomi T., Watanabe T., Murao T., Matsumoto H., et al. Rebamipide improves chronic inflammation in the lesser curvature of the corpus after Helicobacter pylori eradication: A multicenter study. Biomed Res Int. 2015;2015:865146. DOI: 10.1155/2015/865146
26. Han X., Jiang K., Wang B., Zhou L., Chen X., Li S. Effect of rebamipide on the premalignant progression of chronic gastritis: A randomized controlled study. Clin Drug Investig. 2015;35(10):665–73. DOI: 10.1007/s40261-015-0329-z
27. Lee J.S., Jeon S.W., Lee H.S., Kwon Y.H., Nam S.Y., Bae H.I., Seo A.N. Rebamipide for the improvement of gastric atrophy and intestinal metaplasia: A prospective, randomized, pilot study. Dig Dis Sci. 2022 Jun;67(6):2395–402. DOI: 10.1007/s10620-021-07038-7
28. Seo G.H., Lee H. Chemopreventive effect of rebamipide against gastric cancer in patients who undergo endoscopic resection for early gastric neoplasms: A nationwide claims study. Digestion. 2019;100(4):221–8. DOI: 10.1159/000495288
29. Du Y., Li Z., Zhan X., Chen J., Gao J., Gong Y., et al. Anti-inflammatory effects of rebamipide according to Helicobacter pylori status in patients with chronic erosive gastritis: A randomized sucralfate-controlled multicenter trial in China-STARS study. Dig Dis Sci. 2008;53(11):2886– 95. DOI: 10.1007/s10620-007-0180-z
30. Kim G.H., Lee H.L., Joo M.K., Park H.J., Jung S.W., Lee O.J., et al. Efficacy and safety of rebamipide versus its new formulation, AD-203, in patients with Erosive gastritis: A randomized, Double-blind, active control, noninferiority, multicenter, phase 3 study. Gut Liver. 2021;15(6):841–50. DOI: 10.5009/gnl20338
31. Zhang S., Qing Q., Bai Y., Mao H., Zhu W., Chen Q., Zhang Y., Chen Y. Rebamipide helps defend against nonsteroidal anti-inflammatory drugs induced gastroenteropathy: A systematic review and meta-analysis. Dig Dis Sci. 2013;58(7):1991–2000. DOI: 10.1007/s10620-013-2606-0
32. Oh D.J., Yoon H., Kim H.S., Choi Y.J., Shin C.M., Park Y.S., et al. The effect of rebamipide on non-steroidal anti-inflammatory drug-induced gastro-enteropathy: A multi-center, randomized pilot study. Korean J Intern Med. 2022;37(6):1153–66. DOI: 10.3904/kjim.2021.216
33. Jaafar M.H., Safi S.Z., Tan M.P., Rampal S., Mahadeva S. Efficacy of rebamipide in organic and functional dyspepsia: A systematic review and meta-analysis. Dig Dis Sci. 2018;63(5):1250–60. DOI: 10.1007/s10620017-4871-9
Review
For citations:
Lapina Т.L., Ivashkin V.T. Rebamipide during chronic gastritis: H. pylori eradication therapy and restoration of gastric mucosa barrier function. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2023;33(6):81-87. https://doi.org/10.22416/1382-4376-2023-33-6-81-87
Views:
4867
Email this article 
